Literature DB >> 19608554

Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.

S Sakaguchi1, F Garcia-Bournissen, R Kim, U I Schwarz, P C Nathan, S Ito.   

Abstract

Genetic polymorphisms of uridine diphosphate glucuronosyl transferase 1A1 (UGT1A1), and SLCO1B1 coding organic anion-transporter polypeptide 1B1, are independent risk factors known to increase irinotecan toxicity in adults. Although combined occurrence of polymorphisms in these 2 genes is likely to influence susceptibility to irinotecan toxicity, data are scarce, especially in children. We report an 11-year-old female with severe and prolonged neutropenia after irinotecan-based chemotherapy. The patient's genotyping revealed polymorphisms in both UGT1A1 and SLCO1B1. To our knowledge, this is the first case report of combined genotyping of both UGT1A1 and SLCO1B1 in a child with severe irinotecan toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19608554     DOI: 10.1136/adc.2009.163089

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  4 in total

1.  Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation.

Authors:  Pamala A Jacobson; David Schladt; William S Oetting; Robert Leduc; Weihau Guan; Arthur J Matas; Vishal Lamba; Roslyn B Mannon; Bruce A Julian; Ajay Israni
Journal:  Transplantation       Date:  2011-02-15       Impact factor: 4.939

Review 2.  Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy.

Authors:  Baron Bechtold; John Clarke
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-01-20       Impact factor: 4.481

3.  OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.

Authors:  W A Teft; S Welch; J Lenehan; J Parfitt; Y-H Choi; E Winquist; R B Kim
Journal:  Br J Cancer       Date:  2015-01-22       Impact factor: 7.640

4.  Targeted next generation sequencing as a tool for precision medicine.

Authors:  Markus Gulilat; Tyler Lamb; Wendy A Teft; Jian Wang; Jacqueline S Dron; John F Robinson; Rommel G Tirona; Robert A Hegele; Richard B Kim; Ute I Schwarz
Journal:  BMC Med Genomics       Date:  2019-06-03       Impact factor: 3.063

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.